Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Stomach Neoplasms 34Carcinoma, Hepatocellular 33Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Esophageal Squamous Cell Carcinoma 12Lung Neoplasms 9Rectal Neoplasms 8Nasopharyngeal Carcinoma 8Esophageal Neoplasms 6Cholangiocarcinoma 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Carcinoma 3Breast Neoplasms 3Spinocerebellar Degenerations 2Sarcoma 2Recurrence 2Nonsquamous Non-Small Cell Lung Cancer 2Neuroendocrine Tumors 2Lymphoma, T-Cell, Peripheral 2Locally Advanced Rectal Cancer 2

Interventions

Gemcitabine 9Carboplatin 8Paclitaxel 6Capecitabine 4Bevacizumab 4pembrolizumab 3Irinotecan 3Erlotinib Hydrochloride 3atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Filgrastim 2Cisplatin 2CP protocol 2tislelizumab 1tegafur-gimeracil-oteracil 1spartalizumab 1sintilimab 1pertuzumab 1pemigatinib 1olaparib 1ivosidenib 1ipatasertib 1etoposide phosphate 1entrectinib 1cobimetinib 1belinostat 1antineoplaston AS 2-1 1antineoplaston A10 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms, Unknown Primary × sintilimab × Clear all
NCT05024968 2026-02-25

Sintilimab in Cancer of Unknown Primary

M.D. Anderson Cancer Center

Phase 2 Completed
10 enrolled 9 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡